To target the pathogenesis of delayed wound healing in DM, we hypothesized that the combination of a BRD9 degrader in the early inflammatory phase and SAG in the later regeneration phase could be an ideal therapy for effective skin regeneration in DM. This evidence concerns the gene BRD9 and diabetes mellitus.